Upfront Briefing
AstraZeneca spent three years arguing a PD-1xCTLA-4 bispecific could do Yervoy's job without Yervoy's toxicity. The tolerability worked. The efficacy did not, and the monitoring committee pulled the plug on a first-line lung trial this morning before either primary endpoint had a chance to embarrass anyone further. Friday was kinder to the small end of the market. Capricor told the FDA it would rather be judged on arms than hearts and roughly doubled intraday; Redx got to Nasdaq sideways through Skye Bioscience with $125M attached, leaving legacy Skye holders about 5.4% of it. Sandoz, meanwhile, licensed its way into up to 10 Henlius biosimilars this morning.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,785.8 |
(0.2%) |
13.5% |
| Nasdaq 100 |
30,046.1 |
(0.1%) |
19.2% |
| Russell 2000 |
3,068.4 |
0.5% |
22.3% |
| Healthcare (XLV) |
167.4 |
(0.6%) |
7.6% |
| Biotech (XBI) |
157.4 |
0.4% |
29.5% |
| Nasdaq Biotech (NBI) |
6,799.4 |
(0.2%) |
19.1% |
| Clinical Trials (BBC) |
52.9 |
1.0% |
40.5% |
|
- Biotech split by market cap rather than moving as a bloc: XBI +0.4% and BBC +1.0% on single-name catalysts — Capricor up roughly 68% on its Duchenne BLA amendment, Skye Bioscience's $125M Redx combination the same morning — while large-cap NBI (0.2%) and XLV (0.6%) both edged lower.
- July retail sales fell 0.6% to $763.6B on 14 August against a +0.1% consensus, and the University of Michigan's preliminary August sentiment reading came in softer, pulling the S&P 500 back from Thursday's record 7,798.99 close; Broadcom fell about 6% and September crude firmed 1.4% to $82.40.
- Market data: U.S. cash close Friday, 14 August 2026.
The Big 3
|
1
|
AstraZeneca pulls its PD-1xCTLA-4 bispecific out of first-line lung
|
- AstraZeneca (AZN) discontinued its Phase 3 trial of volrustomig plus chemotherapy versus Keytruda plus chemotherapy in first-line metastatic NSCLC after the IDMC found the regimen unlikely to hit either dual primary endpoint — PFS and OS in PD-L1-negative patients. The trial randomised 895 patients. No efficacy data were released.
- Why it matters: This was a futility call on both primary endpoints in PD-L1-negative disease, which was the entire thesis. AstraZeneca built volrustomig to deliver Yervoy-grade CTLA-4 blockade without Yervoy-grade toxicity; the tolerability held and the efficacy didn't. That reads across to rilvegostomig, the PD-1xTIGIT bispecific Guggenheim flagged as low-expectation in a 2 June note, and hands the next-generation IO narrative back to the PD-1xVEGF camp at Summit and Akeso. Cervical, head and neck and mesothelioma Phase 3s continue, so the asset narrows rather than dies. Withholding the numbers is its own tell.
- Source: Fierce Biotech
- More: AstraZeneca
|
|
2
|
Capricor swaps the heart claim for the arm claim
|
- Capricor (CAPR) will amend its deramiocel BLA with 24-month HOPE-3 extension data and seek a refined indication in upper-limb skeletal muscle function, after a 9–3 adcomm vote against the cardiomyopathy claim on 29 July; FDA has said it will extend the 22 August PDUFA date once the amendment is received.
- Why it matters: Capricor is trading the cardiomyopathy claim for an upper-limb one. The amendment leans on a PUL 2.0 result — 4.55-point mean difference, p=0.029 — that The Lancet published the same week, which is the evidence the adcomm never formally weighed. Because FDA moves the date rather than rules on 22 August, the binary shifts right instead of resolving. Cantor went to Overweight with a $28 target from $3.50. Against $237.9M of cash at 30 June and a saleable priority review voucher, the live risk is a second CRL on a narrower label, not a funding wall.
- Source: Fierce Biotech
- More: BioSpace; BioCentury
|
| 3 | Redx backs into Nasdaq through Skye with $125M attached |
- Skye Bioscience (SKYE) will acquire UK-based Redx Pharma via a scheme of arrangement and rebrand as Fibrx Therapeutics, backed by roughly $125M in financings and led by Redx management; lead asset RXC008 is a GI-restricted pan-ROCK inhibitor in fibrostenotic Crohn's with an open U.S. IND, Fast Track and Phase 2 topline due H2 2028. Close expected Q4 2026.
- Why it matters: Read the ownership split before the headline number. Pre-deal Skye holders end up with about 5.38% of Fibrx; Redx holders take 46.17% and the financing syndicate 48.45%. Skye shareholders get a CVR worth 90% of any future nimacimab monetisation plus a 1-for-8 reverse split to hold the Nasdaq bid. The $125M is three pieces — a $67.9M concurrent private round, a $36M Redx Series A and a $22M equity line — funding into 2029. Redx tried this route once before and failed; that a UK biotech is again choosing a scheme over a listing says the IPO window is still only half open.
- Source: Endpoints
- More: Fierce Biotech; BioSpace
|
Everything Else that broke
- Amgen's Tavneos lost its EU authorisation over ADVOCATE data handling — EMA documents describe unblinded personnel re-adjudicating nine patients after database lock, flipping a non-significant week-52 result to significant — while FDA's parallel withdrawal proceeding runs on. — BioSpace
- MapLight paused discovery work to back phase 3-ready ML-007C-MA in schizophrenia and Alzheimer's disease psychosis. — Fierce Biotech
- Cytokinetics (CYTK) sued Bristol Myers and MyoKardia in Delaware seeking a declaratory judgment that its marketed Myqorzo (aficamten) does not infringe BMS's newly granted '697 patent, and that the patent is invalid. — Endpoints
- Biogen's felzartamab won its first global approval in China for second-line multiple myeloma. — Endpoints
- ICER said AstraZeneca's Baxfendy is not cost-effective at its cited $10,950 annual price. — Endpoints
- AbelZeta regained global rights to C-CAR039 and cleared an FDA IND in LBCL. — PR
- Veloxis agreed to pay $46M in a qui tam action tied to admitted kickbacks. — PR
- AI-enabled medical software is pushing regulators toward new AI-specific authorization routes. — BioSpace
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Sandoz took ex-China registration and commercialisation rights to up to 10 Henlius mAb and ADC biosimilars, with terms signed on an initial three — cetuximab (HLX05-N), evolocumab (HLX16) and a belimumab biosimilar — plus an option on hyaluronidase HLXTE-HAase1001; upfront, milestones and option fee total up to $322M, with up to $100.5M invoiced to Henlius in 2026. — PR
- Skye and Redx will form Fibrx Therapeutics in a reverse merger backed by $125M financing (see The Big 3). — Fierce Biotech
VC / Private Financings
- Abcuro raised $66M for a Phase 3 of ulviprubart, its anti-KLRG1 antibody, months after the drug missed in inclusion body myositis but showed a signal in patients with less severe disease. — Endpoints
IPOs / Follow-Ons
- No notable biotech IPO pricings or follow-on offerings were identified inside this edition window.
Academic Corner - Upadacitinib 15 mg daily delivered clinically meaningful facial and total-body repigmentation in phase 3 non-segmental vitiligo studies. — Lancet
- A Lancet comment framed oral JAK inhibitors in vitiligo as the start of a new innovation cycle. — Lancet
- A Lancet correspondence argued semaglutide may still hold preventive potential in Alzheimer's disease despite treatment failure. — Lancet
|
